CN114129543A - Application of microneedle patch in regulating and controlling mechanical microenvironment of scar tissue - Google Patents
Application of microneedle patch in regulating and controlling mechanical microenvironment of scar tissue Download PDFInfo
- Publication number
- CN114129543A CN114129543A CN202111458045.XA CN202111458045A CN114129543A CN 114129543 A CN114129543 A CN 114129543A CN 202111458045 A CN202111458045 A CN 202111458045A CN 114129543 A CN114129543 A CN 114129543A
- Authority
- CN
- China
- Prior art keywords
- scar
- microneedle
- treatment
- scar tissue
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 231100000241 scar Toxicity 0.000 title claims abstract description 59
- 230000001105 regulatory effect Effects 0.000 title claims description 4
- 230000001276 controlling effect Effects 0.000 title claims description 3
- 230000001969 hypertrophic effect Effects 0.000 claims abstract description 10
- 208000032544 Cicatrix Diseases 0.000 claims abstract description 6
- 230000037387 scars Effects 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 230000037390 scarring Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 2
- 230000019612 pigmentation Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 2
- 230000003176 fibrotic effect Effects 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 36
- 210000001519 tissue Anatomy 0.000 description 30
- 230000037311 normal skin Effects 0.000 description 12
- 108010022355 Fibroins Proteins 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 229920000747 poly(lactic acid) Polymers 0.000 description 9
- 239000004626 polylactic acid Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 101000889396 Homo sapiens Ankyrin repeat domain-containing protein 1 Proteins 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 238000010146 3D printing Methods 0.000 description 2
- 102100039181 Ankyrin repeat domain-containing protein 1 Human genes 0.000 description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000007542 hardness measurement Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- -1 polydimethylsiloxane Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 238000004154 testing of material Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a scar improving technology, in particular to application of micro-needle sticking to regulation and control of a scar tissue mechanical microenvironment. The invention aims to provide a new choice for improving scars. According to the invention, researches show that the micro-needle patch can regulate and control the microenvironment of the fibrotic tissue, and lays a foundation for further preparing medical supplies for effectively improving hypertrophic scars.
Description
Technical Field
The invention relates to a scar improving technology, in particular to an application of micro-needle sticking to the regulation and control of a mechanical microenvironment of a fibrotic tissue.
Background
Hypertrophic Scarring (HS) is the result of pathological changes in fibrosis of the damaged tissue during repair. The abnormal increase and excessive deposition of extracellular matrix (mainly collagen and fibronectin) in the scar group not only increase the tissue hardness, but also increase the mechanical stress in the extracellular matrix and the strength of stress field derived from the extracellular matrix, so that the mechanical force stimulation of fibroblasts is activated to induce the expression of transforming growth factor (TGF-beta 1), alpha-smooth muscle actin (alpha-SMA) and Connective Tissue Growth Factor (CTGF), the secretion of type I collagen and fibronectin is increased, and the pathological change of fibrosis is further promoted. Conversely, activation of fibroblasts can be inhibited by releasing or reducing mechanical stress, and expression of pro-fibrotic cytokines can be down-regulated. Therefore, regulation of the mechanical microenvironment of scar tissue has become an effective approach to the treatment of hyperplasia.
While treatment regimens such as surgery, stretch garments, laser treatment, massage, etc. have been used to alleviate the scar tissue mechanical microenvironment, they are still far from perfect. For example, z-shaping can effectively distribute the mechanical forces of an incision after scarring, but the incision can result in secondary injury and the potential risk of scarring. The stretch garment can only reduce vascularization and remodel collagen formation over a longer treatment period to achieve an improved aesthetic appearance. Laser destroys disordered collagen by thermal effects, changing the biomechanical environment and ultrastructure of scar tissue, but patients may develop adverse reactions such as bleeding, erythema, purpura and possible ulceration. Furthermore, these methods are highly dependent on the skill of the clinician. To date, a less invasive, convenient and effective treatment for mechanical treatment of hypertrophic scars remains unsolved.
Disclosure of Invention
The invention aims to provide a new choice for improving scars.
The technical scheme of the invention is the application of micro-needle sticking in the regulation of scar tissue mechanical microenvironment.
Specifically, the application is that the microneedle patch negatively regulates and controls the expression of the mechanosensitive gene ANKRD 1.
The invention also provides application of the microneedle patch in preparing a medical article for relieving hypertrophic scar symptoms.
Further, the reduction in hypertrophic scar symptoms is an improvement in scar pigmentation, a reduction in scar stiffness, an increase in scar tissue flexibility, or an increase in scar tissue tensile strength.
The invention has the beneficial effects that: the microneedle patch disclosed by the invention is good in biocompatibility, helps loaded drugs to pass through a collagen barrier and be slowly released in scar tissues, and continuously plays an anti-scar role. The microneedle patch has the characteristics of minimally invasive and painless property, is convenient and quick to use, can be used by a patient, and greatly improves the self-management of scar patients. The untreated scar is red and has obvious difference with normal skin; the color of the skin is gradually improved after the microneedle treatment, and is close to the normal skin. After treatment, the hardness of the scar tissue is also reduced by up to 35.3% compared to before treatment. Meanwhile, the ductility of scar tissues is improved, the ultimate tensile stress reaches 7.85 +/-0.78 MPa, and the ultimate tensile stress is increased by 2 times. At the microscopic level, down-regulation of the mechanical force sensitive gene ANKRD rd1 suggests a decrease in mechanical force in the tissue microenvironment.
Drawings
Figure 1 skin color measurements of scar tissue after microneedle patch treatment. L value represents an L value, namely L is lighting, and the larger the L value is, the more white is represented; the value A represents the value of A, i.e. A: redness, and the larger the value A, the more red. Control means scar group without microneedle treatment, PLA means polylactic acid microneedle treatment group, PLGA means polylactic-glycolic acid polymer microneedle treatment group, SF means silk fibroin microneedle treatment group, and Normal skin means Normal skin.
Figure 2 hardness measurements after microneedle patch treatment. Scar hardness is expressed as Scar hardness, and H is Shore hardness unit. Control means scar group without microneedle treatment, PLA means polylactic acid microneedle treatment group, PLGA means polylactic-glycolic acid polymer microneedle treatment group, SF means silk fibroin microneedle treatment group, and Normal skin means Normal skin.
Figure 3 maximum tensile strength measurements after microneedle patch treatment. Tensile stress represents the Tensile strength of the structure, i.e., the maximum Tensile strength that can be withstood at break, in MPa. Control means scar group without microneedle treatment, PLA means polylactic acid microneedle treatment group, PLGA means polylactic-glycolic acid polymer microneedle treatment group, SF means silk fibroin microneedle treatment group, and Normal skin means Normal skin.
FIG. 4 shows the result of detecting the expression level of the mechanical force sensitive gene ANKRD1 in scar fibroblasts after treatment. ANKRD1 is the target detection gene, and GAPDH is the internal control. Control indicates the scar group without microneedle treatment, and SF indicates the silk fibroin microneedle treatment group.
Detailed Description
Example 1 microneedle patch preparation procedure
Microneedle structure design: the array density is 15 x 15 needles/cm2) The needle body is in a four-pyramid shape, the side length of the bottom of the cone is 300 mu m, and the height of the needle body is 1 mm;
preparing a microneedle male die: preparing microneedle male molds with different array densities by using high-strength resin as a base material and adopting 3D printing;
preparing a microneedle female die: cleaning a male mold for 3D printing with deionized water, pouring PDMS (polydimethylsiloxane) and a curing agent (mass ratio of 10: 1, w/w) above the male mold, curing at 80 ℃ for 2 hours, and demolding to obtain a microneedle female mold.
And (5) preparing the microneedle patch.
Pretreatment of a mold: cleaning and drying the surface of the PDMS female die by deionized water and isopropanol in sequence;
polymer solution infusion: respectively pouring silk fibroin solution (10 percent, w/v), polylactic acid solution (PLA, 6 percent, w/v) and polylactic-co-glycolic acid (PLGA, 3 percent, w/v) into the processed mould, forcing the polymer solution into a micro-cavity of the mould in a vacuum environment, and then completely drying at 60 ℃;
preparing a backing layer: pouring 15% PVA (polyvinyl alcohol) solution above the mould, and centrifuging to make the PVA solution closely contact with the silk fibroin microneedle;
drying and demolding: drying for 2h at 4 ℃, and demoulding to obtain the microneedle patch made of three materials.
EXAMPLE 2 microneedle patch treatment of hypertrophic scar in rabbit ears
The treatment method comprises the following steps:
disease models: hypertrophic scar of rabbit ear;
the treatment process comprises the following steps: firstly, wiping and disinfecting the local scar with iodine, then pressing and penetrating the sterilized microneedle patches made of three different materials into scar tissues, fixing with an adhesive tape, and keeping for 7-30 days;
grouping: control group (scar without microneedle treatment), microneedle treated group (SF, PLA, PLGA).
(II) treatment effect:
as shown in figure 1, after the micro-needle intervention treatment, the L value (the larger the L value is, the more white the skin is) and the A value (the larger the A value is, the more red the skin is) of the scar tissue part are gradually close to the normal skin, and the untreated scar has obvious difference with the normal skin.
The hardness of the scar tissue is measured by a Shore sclerometer (HT-6510 OO), and the results are shown in figure 2, the hardness of the scar tissue of the microneedle treated group is obviously reduced compared with that of the untreated group, particularly, the hardness of the scar (24.6 +/-3.92 HOO) of the silk fibroin microneedle after the intervention treatment is reduced by 35.3% compared with that of the untreated group (38 +/-2.90 HOO), and the hardness of the normal skin is 17.4 +/-2.14 HOO.
The scar tissue is further sampled and prepared into a dumbbell-shaped sample piece with the effective length of not 1cm for the detection of the tissue biomechanics. A tensile test was conducted on the tissue specimen on a universal material testing machine, the specimen was axially stretched at a rate of 1mm/s until the specimen broke, the maximum stress applied at the time of breaking was recorded, and the tensile strength of the tissue was calculated. As shown in figure 3, the maximum strain of the untreated scar was the lowest, the tensile strength was the lowest, 4.19. + -. 0.45 MPa, while the tensile strength of normal skin was 11.37. + -. 0.88 MPa (p < 0.01). After the microneedle treatment, the ductility of the scar tissue is improved, the ultimate tensile stress of the scar tissue treated by the silk fibroin microneedle reaches 7.85 +/-0.78 MPa, and is increased by 2 times compared with the scar tissue not treated.
Continuously exploring the change of the micro-needle physical intervention on the microenvironment of the scar tissue from the molecular level, and detecting the expression level of a mechanical force sensitive gene ANKRD1 in scar tissue fibroblasts (HSFs) by adopting a western blotting method. The results are shown in fig. 4, where the expression level of ANKRD1 in the scar fibroblasts after treatment with the fibroin microneedle was significantly lower than that of the scar fibroblasts without microneedle treatment. The micro-needle is mainly subjected to physical intervention in the treatment process, so that the interaction of mechanical force between a tissue microenvironment and fibroblasts is blocked, and the mechanical force of the surrounding microenvironment sensed by the fibroblasts is reduced, so that the activation of the fibroblasts is hindered, the generation and deposition of cell matrixes are reduced, and the dynamic change of the conversion from hypertrophic scars to normal tissues is promoted.
Claims (4)
1. The micro-needle is applied to regulating and controlling the mechanical microenvironment of scar tissue.
2. The use of claim 2, wherein the microneedle patch negatively regulates the expression of the mechanosensitive gene ANKRD 1.
3. Use of a microneedle patch in the preparation of a medical article for alleviating the symptoms of hypertrophic scars.
4. The use of claim 3, wherein the reduction in the symptoms of hypertrophic scarring is an improvement in scar pigmentation, a reduction in scar stiffness, an increase in scar tissue flexibility, or an increase in scar tissue tensile strength.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111458045.XA CN114129543A (en) | 2021-12-01 | 2021-12-01 | Application of microneedle patch in regulating and controlling mechanical microenvironment of scar tissue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111458045.XA CN114129543A (en) | 2021-12-01 | 2021-12-01 | Application of microneedle patch in regulating and controlling mechanical microenvironment of scar tissue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114129543A true CN114129543A (en) | 2022-03-04 |
Family
ID=80386947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111458045.XA Pending CN114129543A (en) | 2021-12-01 | 2021-12-01 | Application of microneedle patch in regulating and controlling mechanical microenvironment of scar tissue |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114129543A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113198102A (en) * | 2021-05-17 | 2021-08-03 | 上海天引生物科技有限公司 | Method for regulating and controlling mechanical action of microneedle patch and microneedle patch |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110935097A (en) * | 2019-12-03 | 2020-03-31 | 广州新济薇娜生物科技有限公司 | Microneedle patch for improving skin hypertrophic scar and preparation method thereof |
-
2021
- 2021-12-01 CN CN202111458045.XA patent/CN114129543A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110935097A (en) * | 2019-12-03 | 2020-03-31 | 广州新济薇娜生物科技有限公司 | Microneedle patch for improving skin hypertrophic scar and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| ZHENG LI, ET AL.: "Topical application of silk fibroin-based hydrogel in preventing hypertrophic scars", COLLOIDS AND SURFACES B: BIOINTERFACES * |
| 吴可可 等: "聚合物基仿生医用胶黏剂的开发与应用", 功能高分子学报 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113198102A (en) * | 2021-05-17 | 2021-08-03 | 上海天引生物科技有限公司 | Method for regulating and controlling mechanical action of microneedle patch and microneedle patch |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Houshyar et al. | Peripheral nerve conduit: materials and structures | |
| Yi et al. | Scaffolds for peripheral nerve repair and reconstruction | |
| EP3490624B1 (en) | Nerve guidance conduits, methods of production and uses thereof | |
| Dinis et al. | 3D multi-channel bi-functionalized silk electrospun conduits for peripheral nerve regeneration | |
| US6712850B2 (en) | Porous tissue scaffolds for the repair and regeneration of dermal tissue | |
| US20200324021A1 (en) | 3D Printed Scaffold Structures and Methods of Fabrication | |
| CA2296704A1 (en) | Cardiac muscle regeneration using mesenchymal stem cells | |
| CN103800097A (en) | Fibrous membrane for tissue repair and manufacturing method and application thereof | |
| EP2307065A2 (en) | Compositions and methods for tissue filling and regeneration | |
| WO2006116210A2 (en) | Dermal fillers for biomedical applications in mammals and methods of using the same | |
| CN114129543A (en) | Application of microneedle patch in regulating and controlling mechanical microenvironment of scar tissue | |
| Schmitt et al. | Current applications of polycaprolactone as a scaffold material for heart regeneration | |
| CN113425897A (en) | Active oxygen responsiveness degradable polyurethane heart patch for myocardial infarction repair and preparation method thereof | |
| Cheema et al. | Collagen: applications of a natural polymer in regenerative medicine | |
| WO2007111407A1 (en) | Thread with open pore for plastic surgery | |
| EP1643935A1 (en) | A device for promoting regeneration of an injured nerve, a kit and a biodegradable sheet for preparing such a device | |
| CN115297903B (en) | Hybrid heterogeneous hydrogels, methods of making the same, and their use as non-degradable in situ filled implants | |
| KR20130109850A (en) | Kit comprising recombinant human bone morphogenetic protein for skin repair as active ingredient | |
| CN115737925B (en) | Sclera reinforcement material and preparation method and application thereof | |
| EP2491110A1 (en) | Method for manufacturing a device for regenerating biological tissues | |
| CN114129505A (en) | Silk fibroin microneedle patch for improving hypertrophic scars and preparation method thereof | |
| JP5909610B2 (en) | Collagen sponge | |
| US20210062152A1 (en) | Three-dimensional cell spheroid with high proliferation activity, and producing method and use therefor | |
| AU2017222108B2 (en) | Method of implantation of cell aggregates and tissue fragments | |
| WO2011047970A1 (en) | Method for manufacturing a device for regenerating biological tissues, particularly for regenerating tissues of the central nervous system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220304 |